19-007D5_Primary
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.400
- DNA_REPAIR+0.240
- UV_RESPONSE_UP+0.220
- SPERMATOGENESIS+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.180
- MITOTIC_SPINDLE+0.150
- GLYCOLYSIS+0.140
- WNT_BETA_CATENIN_SIGNALING+0.050
- NOTCH_SIGNALING+0.030
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.530
- ALLOGRAFT_REJECTION-0.520
- IL6_JAK_STAT3_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.420
- IL2_STAT5_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- TGF_BETA_SIGNALING-0.380
- OXIDATIVE_PHOSPHORYLATION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A15S-01A-11R-A115-07 | — | B | 0.872 |
| 2 | C3N-03886 | — | cohortMD1 | 0.870 |
| 3 | TCGA-NK-A5D1-01A-11R-A26W-07 | — | cohortMD1 | 0.869 |
| 4 | SRR1797244 | — | cohortSC | 0.867 |
| 5 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.861 |
| 6 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.861 |
| 7 | TCGA-50-5946-01A-11R-1755-07 | — | cohortA1 | 0.860 |
| 8 | SRR650141 | — | — | 0.860 |
| 9 | SRR650202 | — | — | 0.854 |
| 10 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |